Diabetes-Associated Urinary Tract Infection: Host-Pathogen Biology, Clinical Phenotypes, and Complication Prevention

Nariman Nabil Mohamed Hassan, MSc1; Hassan Mahmoud Hassanin, MD1; Abdalla Moatasem Nawara, MD1; Amira Hamed Mohamed Afifi, MD2

1 Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt

2 Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Received: 28 October 2024, **Accepted:** 17 November 2024, **Published:** 20 November 2024

Abstract

Background: Diabetes mellitus increases susceptibility to urinary tract infection (UTI), but the excess risk is not explained by hyperglycemia alone. Immune dysfunction, glycosuria, autonomic bladder dysfunction, vascular and renal disease, instrumentation, and repeated antimicrobial exposure interact with uropathogen virulence to produce a broad clinical spectrum.

Aim: To synthesize the mechanisms, clinical phenotypes, diagnostic pitfalls, severe complications, and prevention priorities of diabetes-associated UTI in adults.

Methods: A focused narrative review was developed from the supplied doctoral protocol and thesis review, with bibliographic correction and targeted updating using major clinical guidelines, systematic reviews, cohort studies, and pivotal trials.

Results: Adults with diabetes have a consistently higher burden of bacteriuria and symptomatic UTI, although effect estimates vary by sex, age, setting, diabetes duration, glycemic control, and case definition. Diabetes modifies host defense through impaired neutrophil activity, inflammatory dysregulation, glycosuria, altered urothelial signaling, and diabetic cystopathy. Escherichia coli remains dominant, while Klebsiella, Enterococcus, Candida, polymicrobial infection, upper-tract disease, recurrence, bacteremia, and emphysematous infection become more relevant in selected high-risk patients. Asymptomatic bacteriuria should not be screened for or treated solely because diabetes is present. Management should be syndrome-based, culture-informed, renal-function aware, and coupled with source control and metabolic stabilization.

Conclusion: Diabetes is a risk amplifier rather than a uniform definition of complicated UTI. Clinical severity, urinary obstruction or retention, prior microbiology, renal function, and systemic instability should determine investigation and treatment intensity.

Keywords: diabetes mellitus; urinary tract infection; asymptomatic bacteriuria; diabetic cystopathy; pyelonephritis

Introduction

Diabetes mellitus and urinary tract infection intersect at a clinically important point: a common metabolic disease alters the probability, presentation, and consequences of one of the most frequent bacterial syndromes in adult medicine. The relationship is often simplified to the statement that glucose in urine feeds bacteria. That explanation is incomplete. Infection risk emerges from the combined effects of hyperglycemia, immune dysfunction, age, sex, renal impairment, autonomic neuropathy, impaired bladder emptying, healthcare exposure, and urological abnormalities. The resulting phenotype ranges from incidental bacteriuria to cystitis, pyelonephritis, renal abscess, emphysematous infection, and urosepsis. [1,3,4]

The clinical challenge is not merely recognizing increased risk. It is deciding when bacteriuria represents disease, which patients require culture or imaging, when diabetes meaningfully changes the risk category, and how infection management should be integrated with renal and glycemic care. Treating every positive urine culture as infection exposes patients to adverse effects and resistance; treating systemic UTI too narrowly or overlooking obstruction can be equally harmful. A useful review must therefore link mechanism to bedside decisions rather than place all adults with diabetes into one undifferentiated 'complicated UTI' group. [4,13,18,24]

This narrative synthesis was anchored in the supplied protocol comparing diabetic and nondiabetic hospitalized adults and in its accompanying review. Citations were checked for duplication, bibliographic inconsistency, and claim fit, then supplemented with contemporary guidelines and higher-level evidence. Because much of the diabetes-specific UTI literature is observational and definitions differ across studies, associations are interpreted cautiously and are not treated as proof that diabetes independently causes each microbiological or clinical outcome. [4,5,24]

Aim

This review aims to provide internists with an integrated framework for understanding why UTI is more frequent and potentially more severe in adults with diabetes, while separating evidence-based clinical action from assumptions that lead to unnecessary cultures, antibiotics, or prolonged treatment.

Epidemiologic Burden and Clinical Context

The expanding global burden of type 2 diabetes enlarges the population exposed to infection-related morbidity. Egypt is especially relevant because diabetes prevalence is high, diagnosis is often delayed, and renal, vascular, and neuropathic complications frequently coexist by the time patients require hospital care. These factors may concentrate UTI risk in internal medicine wards and intensive care units, where catheters, prior antibiotics, acute kidney injury, and systemic illness further modify the spectrum seen in community studies. [1,2]

Systematic reviews and large database studies consistently indicate more UTI among adults with type 2 diabetes, but the magnitude varies substantially. Differences in whether studies count symptoms, prescriptions, laboratory-confirmed episodes, recurrent events, or asymptomatic bacteriuria explain part of this heterogeneity. Women retain the highest absolute incidence, while the relative effect of diabetes can be striking in men because their baseline risk is lower. Older

age, longer diabetes duration, poor control, recurrent infection, and microvascular complications commonly identify higher-risk subgroups, although the independent contribution of each variable is not uniform across cohorts. [4-7]

A useful interpretation is that diabetes shifts the probability distribution rather than creating a unique disease. Many patients with well-controlled diabetes, preserved renal function, normal voiding, and localized cystitis behave similarly to patients without diabetes. Conversely, a patient with autonomic neuropathy, a high post-void residual, chronic kidney disease, recent hospitalization, and fever has several converging pathways to treatment failure and systemic infection. This distinction supports individual risk stratification instead of automatic escalation based on the diagnostic label alone. [13-15]

Host Defense in the Hyperglycemic State

Innate immune dysfunction is central to infection susceptibility in diabetes. Persistent hyperglycemia alters neutrophil chemotaxis, endothelial adhesion, phagocytosis, degranulation, oxidative burst, and intracellular killing. Monocyte and macrophage signaling is also disturbed, while complement function and antimicrobial peptide activity may be impaired in metabolically unfavorable environments. The result is not simple immunosuppression: basal inflammation may be increased at the same time that coordinated pathogen clearance becomes less effective. [8-11]

Adaptive responses are also altered. Changes in T-cell activation, cytokine balance, antigen presentation, and immunometabolism can weaken the transition from early innate containment to durable pathogen control. Obesity, which frequently accompanies type 2 diabetes, adds adipose-derived inflammatory signaling and may deepen immune dysregulation. These effects are biologically plausible contributors to recurrence and severe infection, but most human studies cannot fully separate diabetes from age, obesity, chronic kidney disease, and healthcare exposure. [9-11]

Glycemic control provides an important clinical bridge between mechanism and outcome. In large primary care cohorts, infection risk rises across worsening HbA1c categories, with the greatest burden at very poor control. HbA1c, however, should not be interpreted as an acute infection biomarker or a stand-alone threshold for antibiotic decisions. It represents chronic metabolic exposure and correlates with diabetes duration, complications, treatment complexity, and socioeconomic barriers. Its value is therefore prognostic and preventive rather than diagnostic of UTI. [8]

Acute infection then feeds back on metabolic control. Counter-regulatory hormones and inflammatory mediators increase hepatic glucose output and insulin resistance, while anorexia, vomiting, dehydration, and changes in renal function make usual glucose-lowering regimens unsafe or inadequate. Severe UTI can precipitate diabetic ketoacidosis or hyperosmolar hyperglycemic state, and these emergencies may dominate the initial presentation. Simultaneous treatment of infection, volume depletion, electrolyte disturbance, and hyperglycemia is therefore essential rather than sequential. [10,13,22]

Table 1. Mechanisms linking diabetes to urinary tract infection

Domain	Diabetes-related change	Clinical implication
Host immunity	Impaired neutrophil recruitment, phagocytosis, oxidative killing, and coordinated cytokine responses	Higher susceptibility and slower clearance, especially with poor control or severe comorbidity
Urinary ecology	Glycosuria and altered urinary metabolites	May support growth or virulence, but glycosuria alone does not diagnose infection
Urothelial defense	Oxidative and microvascular injury with disturbed barrier signaling	Potentially weaker early mucosal containment
Bladder function	Reduced sensation, impaired detrusor contractility, and elevated residual urine	Recurrence, occult retention, and need for bladder assessment
Renal/urological disease	Chronic kidney disease, stones, obstruction, and instrumentation	Greater risk of systemic infection, treatment toxicity, and source-control failure
Healthcare exposure	More admissions, procedures, cultures, and antibiotics	Selection and acquisition of resistant organisms

Mechanisms overlap; no single pathway is necessary or sufficient. The dominant clinical drivers differ among patients. [8-15]

The Diabetic Urinary Tract as an Ecologic Niche

Glycosuria changes urinary ecology, but its consequences depend on glucose concentration, urine flow, bacterial species, host immunity, and voiding efficiency. Glucose can support bacterial growth and influence expression of adhesins and biofilm-related traits, yet urinary glucose alone does not establish infection. This distinction is clinically visible in trials of sodium-glucose cotransporter 2 inhibitors: genital mycotic infection clearly increases, whereas the effect on bacterial UTI is smaller, inconsistent across agents and analyses, and not sufficient to justify routine discontinuation in stable patients. [3,12,25-27]

Uropathogenic Escherichia coli remains successful because it is adapted to the urinary tract. Type 1 fimbriae with the FimH adhesin mediate attachment to bladder epithelium; P fimbriae facilitate upper-tract tropism; iron-acquisition systems, toxins, motility, intracellular bacterial communities, and quiescent reservoirs promote persistence and recurrence. Diabetes may amplify the consequences of these virulence programs by weakening clearance, but the organism's intrinsic biology remains the foundation of disease. [3,12,31,33]

The urothelium is an active immune interface rather than a passive barrier. Pattern-recognition receptors, cytokines, exfoliation, mucosal glycosaminoglycans, and antimicrobial peptides coordinate early defense. Chronic metabolic injury, microvascular disease, and oxidative stress may disturb this response. Evidence is strongest for broad immune and tissue effects of diabetes; claims that a specific urothelial defect independently determines human UTI outcomes remain less secure and should be framed as mechanistic plausibility rather than settled clinical fact. [9,10,12]

Diabetic cystopathy supplies a second major pathway. Autonomic neuropathy may reduce bladder sensation, delay voiding, increase capacity, impair detrusor contractility, and raise post-void residual volume. Urinary stasis then permits prolonged bacterial contact and undermines eradication. The phenotype is heterogeneous: early disease may include urgency or detrusor

overactivity, while advanced disease more often produces impaired emptying. Recurrent UTI, weak stream, hesitancy, overflow symptoms, or unexplained upper-tract dilatation should prompt assessment of voiding function rather than repeated empirical antibiotics alone. [14]

Microbiology and Clinical Phenotypes

E. coli remains the leading pathogen in adults with and without diabetes. Across diabetes-specific studies, however, Klebsiella species, Enterococcus species, Candida species, and polymicrobial cultures are reported more often in selected hospital, catheterized, recurrent, or poorly controlled populations. These shifts should not be generalized to every outpatient. They frequently reflect case mix, prior antimicrobial exposure, devices, urinary retention, and hospitalization rather than a direct biological effect of diabetes alone. [4,12,13]

Localized cystitis usually presents with dysuria, frequency, urgency, and suprapubic discomfort without systemic features. Pyelonephritis or systemic UTI should be considered when fever, rigors, flank pain, vomiting, hemodynamic change, delirium, or acute kidney injury is present. Neuropathy, older age, and severe metabolic disturbance can blunt classic urinary symptoms, so deterioration in glycemic control or functional status may be a clue; nevertheless, nonspecific symptoms should not substitute for a clinical search for other infection sources. [13,24,34]

Candiduria deserves separate interpretation. Diabetes, glycosuria, antibiotics, urinary devices, and critical illness favor Candida detection, but most asymptomatic candiduria represents colonization. Treatment is generally reserved for symptomatic infection or selected high-risk situations, and catheter removal or correction of obstruction may matter more than antifungal prescription. Species identification becomes important when treatment is required because non-albicans Candida may have reduced azole susceptibility. [21]

Asymptomatic Bacteriuria: A Test of Diagnostic Discipline

Asymptomatic bacteriuria is defined by quantitative bacterial growth in appropriately collected urine without symptoms attributable to UTI. Pyuria does not convert asymptomatic bacteriuria into symptomatic infection because inflammatory cells accompany colonization in many older, diabetic, and catheterized patients. A positive culture is therefore a microbiological result, not a clinical diagnosis. This principle prevents urine testing from becoming an automatic pathway to antibiotics. [18,24]

Diabetes increases the prevalence of asymptomatic bacteriuria, particularly in women and in those with longer disease duration or microvascular complications. Earlier observational work raised concern that untreated bacteriuria might accelerate renal decline or predict pyelonephritis. Subsequent evidence did not show that antibiotic treatment improves clinically important outcomes, and apparent associations with albuminuria or renal disease are vulnerable to confounding because the same patients are more likely to have both diabetic complications and bacteriuria. [16,19,20]

The pivotal randomized trial in diabetic women found that treating asymptomatic bacteriuria did not reduce symptomatic UTI or important complications, while it substantially increased antimicrobial exposure. Contemporary infectious diseases and urological guidelines therefore

recommend against screening or treating asymptomatic bacteriuria solely because a patient has diabetes. Established exceptions concern pregnancy and selected invasive urological procedures associated with mucosal trauma, not diabetes itself. [17,18,24]

This recommendation has practical consequences in hospital medicine. Urine culture should not be ordered for isolated cloudy urine, odor, pyuria, chronic incontinence, or nonspecific fatigue without a compatible syndrome. In an older patient with delirium, clinicians should assess fever, hemodynamics, localizing urinary features, retention, medication effects, dehydration, and other infection sources. Avoiding low-value cultures is often more effective stewardship than trying to ignore a positive result once it appears in the chart. [18,24,34]

Table 2. Syndrome-based interpretation in adults with diabetes

Clinical state	Key findings	Recommended response
Asymptomatic bacteriuria	Positive culture without attributable urinary symptoms	Do not screen or treat solely because of diabetes; apply established exceptions
Localized cystitis	Dysuria, frequency, urgency, suprapubic pain; no systemic features	Select oral therapy using prior cultures, local susceptibility, interactions, and renal function
Systemic UTI/pyelonephritis	Fever, rigors, flank pain, vomiting, hypotension, delirium, or organ dysfunction	Culture, prompt effective therapy, metabolic assessment, and evaluate for obstruction
Recurrent UTI	Repeated symptomatic, preferably culture-confirmed episodes	Confirm diagnosis; review resistance, retention, stones, atrophy, and catheter exposure
Emphysematous/abscess phenotype	Toxic appearance, shock, AKI, thrombocytopenia, gas or collection on imaging	Resuscitation, broad therapy, urgent drainage/source control, multidisciplinary care

AKI, acute kidney injury; UTI, urinary tract infection. [18,22-24,28]

Severe and Complicated Disease

Diabetes is strongly represented among patients with emphysematous pyelonephritis, a necrotizing infection characterized by gas in the renal parenchyma, collecting system, or perinephric tissues. Poor tissue perfusion, impaired immunity, glucose availability, and gas-forming organisms create a plausible pathogenic combination. Clinical deterioration, shock, thrombocytopenia, altered mental state, acute kidney injury, obstruction, or failure to improve should lower the threshold for cross-sectional imaging. [22,23]

Management of emphysematous infection has shifted from routine emergency nephrectomy toward rapid resuscitation, effective broad-spectrum antibiotics, urgent relief of obstruction, and image-guided drainage when feasible. Meta-analytic data, derived mainly from observational series, associate conservative and minimally invasive approaches with lower mortality than upfront nephrectomy, but confounding by severity is unavoidable. Nephrectomy remains necessary when source control fails, necrosis is extensive, or clinical instability persists despite appropriate treatment. [23]

Other serious complications include renal or perinephric abscess, papillary necrosis, bacteremia, urosepsis, and acute metabolic decompensation. Their risk is not distributed evenly across all

people with diabetes. Structural obstruction, stones, retention, catheters, advanced kidney disease, delayed presentation, and prior resistant isolates often provide more immediate guidance than HbA1c alone. Source control and timely recognition of systemic infection are therefore decisive determinants of outcome. [13,22,24]

Diagnostic and Management Framework

Diagnosis begins with syndrome definition. Localized lower-tract symptoms without fever or systemic instability support cystitis; fever, rigors, flank pain, hypotension, organ dysfunction, or bacteremia indicate systemic involvement. Urinalysis can support but not establish the diagnosis. Urine culture is particularly valuable in men, pyelonephritis, systemic illness, recurrent infection, recent antibiotics, prior resistant organisms, urinary devices, renal impairment, pregnancy, or treatment failure. [3,13,24]

A properly collected specimen is essential. Midstream clean-catch urine is preferred when feasible; a newly replaced catheter should be sampled in catheter-associated disease rather than the collection bag. Mixed growth may represent contamination, although genuine polymicrobial infection becomes more plausible with long-term devices or structural abnormalities. The result should be interpreted alongside symptoms, collection method, colony count, pyuria, and recent antimicrobial exposure. [18,24]

Imaging is not routine for uncomplicated cystitis. Renal ultrasonography or computed tomography becomes appropriate when obstruction, stone disease, abscess, emphysematous infection, severe sepsis, unexplained kidney injury, recurrent upper-tract infection, or failure to improve is suspected. Bedside bladder scanning is a high-yield extension of examination in patients with voiding symptoms, neuropathy, recurrent infection, or post-renal kidney injury. [14,22-24]

Treatment intensity should follow the phenotype. Stable localized disease can often be managed with an oral agent selected from local susceptibility data and adjusted for kidney function. Systemic disease requires cultures, timely effective therapy, assessment for obstruction, and close metabolic monitoring. Once susceptibilities are available, therapy should narrow promptly. Diabetes alone does not prove that a longer course is necessary; duration should reflect infection site, systemic response, source control, bacteremia, renal abscess, prostatitis, and the patient's trajectory. [13,24]

Glucose management is part of infection care. Insulin requirements may rise during acute illness, while reduced intake and declining kidney function can increase hypoglycemia risk as inflammation resolves. Metformin and sodium-glucose cotransporter 2 inhibitors may need temporary interruption during severe illness, hypoperfusion, ketoacidosis risk, or acute kidney injury. These decisions should be individualized and reassessed before discharge so that temporary changes do not become unintended permanent undertreatment. [25-27]

Clinical Modifiers Across Patient Groups

Sex and reproductive stage substantially modify baseline risk. Women have greater lifetime exposure to ascending infection because of urethral anatomy, sexual activity, and changes in the periurethral ecosystem. After menopause, estrogen deficiency reduces lactobacillus dominance

and alters vaginal mucosal defense, while prolapse, incontinence, and incomplete emptying become more common. Diabetes adds metabolic and neurological risk to these established pathways. A postmenopausal woman with recurrent dysuria should therefore be evaluated for atrophy and voiding dysfunction rather than managed only by rotating antibiotics. [16,30,34]

Older adults present a second diagnostic challenge. Chronic urgency, incontinence, bacteriuria, and pyuria are common, and acute illness may present with functional decline or delirium rather than a clear urinary complaint. These facts increase both under-recognition of systemic infection and overdiagnosis of UTI. A disciplined evaluation should document new localizing symptoms, fever or hemodynamic change, retention, hydration, medication effects, and alternative infection sources. Diabetes raises vulnerability but does not make bacteriuria the default explanation for every nonspecific deterioration. [18,24,34]

UTI in men warrants attention to prostate and outlet disease. Benign prostatic enlargement, urethral stricture, stones, instrumentation, and neurogenic dysfunction may produce urinary stasis. Fever, pelvic or perineal pain, obstructive symptoms, or recurrent infection with the same organism should raise concern for prostatitis or a persistent anatomical focus. Antimicrobials that are adequate for bladder infection may be unsuitable when prostatic penetration is required, making accurate syndrome definition essential before choosing route or duration. [13,24]

Chronic kidney disease changes both risk and management. Reduced concentrating ability, structural disease, and frequent healthcare exposure may increase infection susceptibility, while diminished clearance narrows the therapeutic margin of several antibiotics. Acute infection can cause prerenal injury, sepsis-associated kidney injury, or postrenal obstruction, each requiring a different response. A creatinine value should therefore be interpreted as a changing physiological signal rather than only a dosing input; urine output, volume status, obstruction, and recent baseline function must be considered together. [13,22,24]

Hospitalized and critically ill adults often have the densest concentration of confounders: indwelling catheters, broad-spectrum antibiotics, organ support, impaired consciousness, and multiple potential infection sources. Catheter-associated bacteriuria is expected with duration and should not be treated without a compatible syndrome. When systemic UTI is suspected, catheter replacement, blood cultures in severe illness, and prompt evaluation for obstruction or abscess may improve diagnostic accuracy and source control more than repeated sampling from an old catheter. [18,22,24]

Pregnancy is an established exception to the general rule against treating asymptomatic bacteriuria because therapy reduces pyelonephritis risk and pregnancy complications. Diabetes may further increase obstetric and infectious complexity, but management should follow pregnancy-specific culture thresholds and antimicrobial safety principles. This exception should be stated explicitly because clinicians sometimes incorrectly generalize it to all adults with diabetes, thereby converting a focused evidence-based indication into widespread overtreatment. [18,24]

Recurrent Infection, Treatment Failure, and Follow-up

Recurrent UTI should be defined using symptomatic episodes rather than repeated positive cultures. Reinfection usually reflects a new episode after microbiological clearance, whereas

relapse with the same organism shortly after treatment suggests a persistent reservoir, inadequate tissue exposure, infected stone, obstruction, abscess, prostatitis, or unresolved retention. This distinction changes the evaluation: repeated reinfection emphasizes prevention and exposure reduction, while relapse requires a search for an untreated focus or an inactive regimen. [14,28]

Apparent treatment failure also requires diagnostic reconsideration. Dysuria can arise from vaginitis, genital candidiasis, sexually transmitted infection, chemical irritation, stones, malignancy, or painful bladder syndromes. Persistent fever may reflect obstruction, abscess, resistant bacteria, endocarditis, pneumonia, or another source. Broadening therapy without re-examining the diagnosis risks suppressing cultures, increasing toxicity, and delaying definitive care. The correct response to non-improvement is a structured review of syndrome, source, specimen, susceptibility, exposure, adherence, and anatomy. [3,13,24]

The relationship between glycemic control and recurrence is clinically plausible but should be communicated carefully. Improving HbA1c is beneficial for global diabetes outcomes and probably reduces infection susceptibility at very poor control, yet no specific HbA1c target has been validated as a UTI-prevention intervention independent of overall diabetes care. Short-term intensification that causes hypoglycemia is not justified to sterilize urine. The objective is safe, sustainable metabolic control combined with correction of urinary stasis and unnecessary antimicrobial exposure. [8,14,28]

Post-void residual measurement is underused in recurrent disease. A bedside bladder scan can identify clinically important retention with little burden, although a single reading must be interpreted in relation to voided volume, timing, hydration, and symptoms. Repeatedly elevated residuals justify review of medications, constipation, pelvic organ prolapse, outlet obstruction, and autonomic neuropathy. Urodynamic testing is reserved for selected complex cases because diabetic bladder dysfunction is heterogeneous and cannot be inferred from symptoms alone. [14]

Routine test-of-cure culture after symptom resolution is generally unhelpful outside defined high-risk situations. It detects colonization and invites treatment that does not improve outcomes. By contrast, recurrence with systemic features, early relapse, or persistent symptoms warrants repeat culture before additional antibiotics when feasible. The new isolate should be compared with the earlier organism and susceptibility pattern, because this comparison can distinguish relapse from reinfection and reveal resistance selected during treatment. [18,24,28]

Discharge is a vulnerable transition. Patients leaving hospital after systemic UTI need a reconciled antimicrobial plan, renal-dose confirmation, a documented completion date, and clear instructions about fever, vomiting, oliguria, recurrent flank pain, or worsening glucose. Diabetes medications withheld during acute illness require a restart or review plan. Without explicit ownership, temporary insulin changes, sodium-glucose cotransporter 2 inhibitor interruption, or broad-spectrum antibiotics may continue longer than intended. [24-27]

Implications for Tertiary-Care Research

A hospital comparison of diabetic and nondiabetic adults can be clinically valuable if the analysis separates symptomatic UTI from asymptomatic bacteriuria and contamination. The denominator

should be all eligible patients tested under a consistent protocol, not only positive cultures. Outcomes should be stratified by localized versus systemic infection, community versus healthcare association, catheter status, and first versus recurrent episode. Without these distinctions, prevalence and resistance estimates may reflect testing behavior more than disease biology. [4,18,24]

Risk-factor analyses should prioritize variables measured before the culture result: recent antibiotics, prior isolates, recent hospitalization, urinary catheterization, instrumentation, stones, obstruction, post-void residual, kidney function, diabetes duration, HbA1c, and acute severity. Multivariable models must be parsimonious relative to the number of positive cultures or resistant events. Diabetes-resistance associations should be reported with confidence intervals and interpreted as adjusted associations, not proof of causation. [4,5,13]

Local susceptibility findings are most useful when duplicate isolates are controlled, laboratory methods follow current standards, and the unit of analysis is clear. Reporting all cultured organisms without separating colonization, contamination, and infection can inflate uncommon pathogens. The final output should support an institutional pathway linking syndrome, severity, prior microbiology, and renal function to empirical choice, followed by mandatory culture review and de-escalation. [3,13,24]

Common Misconceptions and Their Clinical Correction

The first misconception is that every UTI in a person with diabetes is necessarily complicated. Diabetes increases risk, but contemporary classification increasingly emphasizes localized versus systemic features and immediately relevant host or anatomical factors. A stable woman with controlled diabetes and isolated cystitis is clinically different from a patient with shock, obstruction, renal impairment, or a catheter. Management should reflect that difference. [13,24]

The second misconception is that glycosuria proves a bacterial growth advantage that must be treated. Glycosuria is a risk context, not a diagnostic criterion, and it may result from hyperglycemia or sodium-glucose cotransporter 2 inhibition. Symptoms, inflammatory response, specimen quality, and anatomical site determine whether infection exists. Treating glucose in urine with antibiotics confuses a metabolic finding with a clinical syndrome. [3,25-27]

The third misconception is that pyuria distinguishes infection from colonization. Pyuria reflects urinary inflammation and is common with asymptomatic bacteriuria, catheters, stones, and other urological conditions. It can support a compatible diagnosis, and absence may lower probability, but no pyuria threshold can replace clinical assessment. Antibiotic decisions based on white-cell counts alone are a major route to overtreatment. [18,24]

The fourth misconception is that a higher colony count means a more severe infection. Quantitative growth helps judge specimen significance, but severity is determined by systemic physiology, infection site, obstruction, organ dysfunction, and host reserve. A patient with bacteremic pyelonephritis may have a lower count after partial treatment, while an asymptomatic patient can have sustained high-count bacteriuria without benefit from therapy. [17,18,24]

The fifth misconception is that longer treatment is safer in diabetes. Excess duration increases adverse effects and selection pressure, and diabetes-specific evidence does not show that routine

extension prevents recurrence. Deep infection, prostatitis, abscess, delayed response, or inadequate source control may require longer therapy; the reason should be named explicitly rather than inferred from diabetes alone. [24,28]

The sixth misconception is that an SGLT2 inhibitor should always be stopped after UTI. Severe acute illness, ketoacidosis risk, hypovolemia, or acute kidney injury may justify temporary interruption. A stable bacterial UTI does not automatically outweigh the drug class's cardiovascular and renal benefits. Recurrent genital mycotic infection and bacterial UTI should also be distinguished because their evidence and management differ. [25-27]

The seventh misconception is that HbA1c can identify the infecting organism or predict susceptibility. Poor control is associated with infection burden, but it does not replace culture when culture is indicated and cannot select an antibiotic. HbA1c belongs in long-term risk reduction and interpretation of host vulnerability, not in a deterministic empirical-treatment rule. [8]

The final misconception is that lack of improvement always means resistance. Inactive therapy is one explanation, but obstruction, abscess, incorrect diagnosis, poor absorption, inadequate dose, nonadherence, or a nonurinary source may be more important. Reassessment should precede escalation. In severe disease, imaging and source control frequently provide more benefit than adding a second broad-spectrum agent. [22-24]

Prevention and Future Directions

Prevention starts with modifiable drivers: sustained glycemic improvement, appropriate hydration when medically safe, regular voiding, correction of retention, avoidance of unnecessary catheterization, and reduction of unnecessary antibiotics. Recurrent UTI warrants confirmation that episodes were truly symptomatic and culture documented, followed by evaluation for stones, obstruction, prolapse, atrophic urogenital changes, or dysfunctional voiding when clinically indicated. Longer antibiotic courses have not been shown to prevent recurrence simply because diabetes is present. [8,14,28]

Non-antibiotic prevention should be individualized. Vaginal estrogen is relevant for postmenopausal women without contraindications; cranberry products probably reduce recurrence in some populations but effect size and formulations vary. Adequate counseling must distinguish genital mycotic effects of sodium-glucose cotransporter 2 inhibitors from bacterial UTI and preserve the substantial cardiorenal benefits of this drug class when no compelling reason for discontinuation exists. [25-30]

Future work should move beyond binary diabetic versus nondiabetic comparisons. Prospective studies need standardized definitions, severity classification, reliable capture of prior antibiotics and cultures, measures of bladder function and renal disease, and adjustment for healthcare exposure. Mechanistic research on urothelial signaling, urinary metabolomics, microbial communities, intracellular reservoirs, and host-pathogen interactions may identify patients who benefit from targeted prevention rather than repeated antimicrobial therapy. [4,12,14,31,33]

Anti-adhesion agents, vaccines, bacteriophages, and microbiome-directed strategies are attractive because they may prevent infection without applying the same selection pressure as conventional antibiotics. Evidence remains developmental: a controlled phage trial in a urological

population did not establish routine clinical use, and FimH-targeted approaches still require robust human efficacy data. These innovations should be presented as research priorities, not substitutes for culture-guided care and source control. [31,32]



Figure 1. Original clinical decision framework synthesized from current evidence and guidelines. [18,24]

Conclusion

Urinary tract infection in diabetes is best understood as the product of interacting metabolic, immune, neurological, renal, urological, and healthcare-related factors. Diabetes increases risk, but it does not make every positive culture clinically meaningful or every episode uniformly complicated. Internists should define the syndrome, identify systemic instability and source-control problems, obtain cultures selectively, protect renal function, and stabilize glycemia. Asymptomatic bacteriuria should not be screened for or treated solely because diabetes is

present. The greatest opportunity for improved outcomes lies in individualized risk assessment: recognizing retention, obstruction, recurrent culture-proven infection, prior resistance, kidney dysfunction, and severe metabolic decompensation early while avoiding unnecessary cultures and antibiotics in low-probability presentations.

References

1. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
2. Hegazi R, El-Gamal M, Abdel-Hady N, Hamdy O. Epidemiology of and risk factors for type 2 diabetes in Egypt. Ann Glob Health. 2015;81(6):814-820.
3. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-284.
4. Paudel S, John PP, Poorbaghi SL, Randis TM, Kulkarni R. Systematic review of literature examining bacterial urinary tract infections in diabetes. J Diabetes Res. 2022;2022:3588297.
5. Salari N, Karami MM, Bokaee S, et al. The prevalence of urinary tract infections in type 2 diabetic patients: a systematic review and meta-analysis. Eur J Med Res. 2022;27(1):20.
6. Hirji I, Guo Z, Andersson SW, Hammar N, Gomez-Caminero A. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database. J Diabetes Complications. 2012;26(6):513-516.
7. Muller LMAJ, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41(3):281-288.
8. Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care. 2018;41(10):2127-2135.
9. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev. 2020;16(5):442-449.
10. Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Front Immunol. 2020;11:1582.
11. Frydrych LM, Bian G, O'Lone DE, Ward PA, Delano MJ. Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality. J Leukoc Biol. 2018;104(3):525-534.
12. Terlizzi ME, Gribaudo G, Maffei ME. Uropathogenic Escherichia coli infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies. Front Microbiol. 2017;8:1566.
13. Nitzan O, Elias M, Chazan B, Saliba W. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Syndr Obes. 2015;8:129-136.
14. Yuan Z, Tang Z, He C, Tang W. Diabetic cystopathy: a review. J Diabetes. 2021;13(4):328-340.
15. Geerlings SE. Urinary tract infections in patients with diabetes mellitus: epidemiology, pathogenesis and treatment. Int J Antimicrob Agents. 2008;31(suppl 1):S54-S57.
16. Boyko EJ, Fihn SD, Scholes D, Abraham L, Monsey B. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am J Epidemiol. 2005;161(6):557-564.
17. Harding GKM, Zhanel GG, Nicolle LE, Cheang M. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med. 2002;347(20):1576-1583.
18. Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):e83-e110.
19. Renko M, Tapanainen P, Tossavainen P, Pokka T, Uhari M. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care. 2011;34(1):230-235.
20. Papazafiropoulou A, Daniil I, Sotiropoulos A, et al. Prevalence of asymptomatic bacteriuria in type 2 diabetic subjects with and without microalbuminuria. BMC Res Notes. 2010;3:169.
21. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50.

22. Mnif MF, Kamoun M, Kacem FH, et al. Complicated urinary tract infections associated with diabetes mellitus: pathogenesis, diagnosis and management. Indian J Endocrinol Metab. 2013;17(3):442-445.
23. Desai R, Batura D. A systematic review and meta-analysis of risk factors and treatment choices in emphysematous pyelonephritis. Int Urol Nephrol. 2022;54(4):717-736.
24. European Association of Urology. EAU Guidelines on Urological Infections. 2026 ed. Arnhem, The Netherlands: EAU Guidelines Office; 2026.
25. Zheng Z, Zong Y, Ma Y, et al. Risk of urinary tract infection in patients with type 2 diabetes mellitus treated with dapagliflozin: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2023;43(4):209-225.
26. Arshad M, et al. Genito urinary infection and urinary tract infection in patients with type 2 diabetes mellitus receiving SGLT2 inhibitors: evidence from landmark randomized clinical trials. Drug Res (Stuttg). 2024;74(7):307-313.
27. Pishdad R, Auwaerter PG, Kalyani RR. Diabetes, SGLT-2 inhibitors, and urinary tract infection: a review. Curr Diab Rep. 2024;24(5):108-117.
28. Papp SB, Zimmern PE. Recurrent urinary tract infections and type 2 diabetes mellitus: a systematic review predominantly in women. Front Urol. 2023;3:1275334.
29. Williams G, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023;11(11):CD001321.
30. Stapleton AE. The vaginal microbiota and urinary tract infection. Microbiol Spectr. 2016;4(6):UTI-0025-2016.
31. Kalas V, Pinkner JS, Hannan TJ, et al. Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions. Sci Adv. 2018;4(3):eaao3637.
32. Leitner L, Sybesma W, Chanishvili N, et al. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021;21(3):427-436.
33. Sivick KE, Mobley HLT. Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect Immun. 2010;78(2):568-585.
34. Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA. 2014;311(8):844-854.